

PHARMANUTRA S.P.A.: RENEWED ITS PARTNERSHIP WITH *AF CORSE*

For the third consecutive year, the Cetilar® brand will be featured on the two official Ferrari 499p cars competing in the 2025 World Endurance Championship.

Pisa, March 21, 2025 - The Board of Directors of [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), a company specializing in the field of iron and mineral nutritional supplements and medical devices for muscles and joints, announces the renewal of its partnership, for the third consecutive year, with the Ferrari-AF Corse Team, which competes with the two official Ferrari 499P Hypercar prototypes in the FIA WEC 2025, the World Endurance Championship that kicked off last week in Doha, Qatar.

The 1812 km of Qatar event immediately showcased the performance of the two Ferrari Hypercars, which achieved a historic victory with the crew formed by Antonio Fuoco, Miguel Molina and Niklas Nielsen in the Ferrari number 50 (already winner of the last 24 Hours of Le Mans) and a third place with Alessandro Pier Guidi, James Calado and Antonio Giovinazzi in the Ferrari n. 51 (first at Le Mans in 2023).

The agreement with Team Ferrari-AF Corse, a partnership that began in 2023, the same year when the Ferrari 499P's debut in the World Endurance Championship, includes the presence of the Cetilar® brand - a line of products based on Cetylated Esters for the wellbeing of muscles and joints, now also in the Nutrition version, a line of supplements designed for those who practice sport constantly - on the two official Hypercars of the prancing horse and on the overalls of the six Ferrari drivers of the two prototypes. But there's more.

As Official Medical Partner of Club Competizioni GT, Med-Ex will in fact take care of the physical preparation and health aspects of the official drivers of the prancing horse and all the team members, using products from the Cetilar® lines, both from the clinical nutrition range and from the other nutritional supplements made by PharmaNutra, leveraging the Sucrosomial® Technology to ensure better tolerability and excellent absorption.

After its debut in Qatar, the FIA World Endurance Championship's next stops will be at Imola (21 April), SPA (Belgium, 11 May), Le Mans (France), for the legendary 24 Hours (15 and 16 June), Sao Paulo (Brazil, 15 July), Austin (USA, 11 September), Fuji (Japan, 28 September) and Bahrain (8 November).

Roberto Lacorte, Vice-President and CEO of PharmaNutra S.p.A., states: *"We believed in Ferrari's Hypercar project from the very beginning, even when it was still in its early stages, because we were confident it was a winning challenge. Now, in our third year of partnership, we can say we were right, as the results achieved by the 499P speak for themselves. Linking our Cetilar® brand to these extraordinary performances achieved by Ferrari, starting with the victories in the last two editions of the Le Mans 24 Hours, is truly a source of great pride and satisfaction for our company".*

Amato Ferrari, Team Principal of AF Corse, comments: *"We believe in partnerships with companies of value, with whom we can build medium to long-term relationships. This is exactly the path we have taken with PharmaNutra and their Cetilar® brand. In 2025, we embark on a new chapter of our long-standing collaboration: together, we have achieved unforgettable successes. Now we look to the future, striving for even greater accomplishments. Winning the opening round of the 2025 World Championship is just the beginning of a new journey".*

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements with the SiderAL® brand, where it can claim important Sucrosomial® Technology patents, and is considered one of the top players in the sector of medical devices dedicated to the restoration of joint capacity thanks to the Cetilar® brand, now on the market also with Cetilar® Nutrition, a line of supplements designed for those who practice sport constantly. Over the years the Group - present abroad in over 89 countries - has developed precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

[PharmaNutra.it](https://pharmanutra.it)

For further information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

investorrelation@pharmanutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com